RARE · Ultragenyx Pharmaceutical Inc.
$15.07
-0.25 (-1.63%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$1.43B
Shares
98.59M
Volume · Sep 30
4.42M
Avg daily vol (3M)
3.73M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$15.32
Open$14.46
Day$14.11–15.50
52W close$12.88–36.54
Avg vol 30d5.6M
Short int16.6M · 16.8% float · 2.2d
Short vol54%
Last earningsAug 4, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 5 wks
filed Aug 5, 2026
call held May 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-49.5%
Trailing year
Short interest
16.8%
Latest settlement · 2.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.38
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−37%
below
Price vs 50-day avg
−30%
below
RSI (14)
37
neutral
MACD trend
Positive
52-week position
10%
near low
Momentum
relative strength
1-month return
−39%
trailing
6-month return
−34%
trailing
YTD return
−33%
this year
Relative strength
−47%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $22 › 200d $24 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +62 funds added
Insider flow
Distributing
Net -$2.3K over 90 days · 100% sells
Short interest
Falling
16.81% of float · ▼ -3.3% MoM · 2.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
317 holders — near 3-yr high, broad support
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+7%
Y/Y
Free cash flow
$-472.0M
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
8.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Total revenue
· full year 2026
Initiated
$730M – $760M
prior FY $673M
midpoint +10.7% Y/Y
Crysvita revenue
· full year 2026
Initiated
$500M – $520M
Dojolvi revenue
· full year 2026
Initiated
$100M – $110M
Guided vs delivered
· last 3 settled
Total revenue
full year 2024
guided $500M – $530M
$560M
Beat +8.7%
Total revenue
full year 2023
guided $425M – $450M
$434M
In line
Revenue in Ultragenyx territories
2021
guided $180M – $190M
$351.41M
Beat +89.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−37%
Bearish
Price vs 50-day avg
−30%
Bearish
RSI (14)
37
Neutral
MACD trend
Positive
Bullish
52-week position
10%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $22 › 200d $24 — 200d above 50d
Institutional flow
Accumulating
+6% holders QoQ · +62 funds added
Insider flow
Distributing
Net -$2.3K over 90 days · 100% sells
Short interest
Falling
16.81% of float · ▼ -3.3% MoM · 2.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
317 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13
Now $15 · 10%
Range high $37
vs 200-day avg -37%
vs 50-day avg -30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RARE
this stock
Ultragenyx Pharmaceutical Inc.
|
$1.43B | -33.4% | +20.2% | — | 16.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +16.2% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -2.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RARE | -1.9% | -39.2% | -33.8% | -39.2% | -33.4% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | -0.7% | -38.9% | -46.9% | -38.9% | -45.5% |
Key facts
CIK
1515673
CUSIP
90400D108
13F (30d)
10 filings
10 filers
Visit website
Investor relations